How Much Does Evenity (Romosozumab) Cost in Nebraska in 2026?

Nebraska Retail Pricing for Evenity in 2026

The average cash-pay price for Evenity across Nebraska retail pharmacies sits at $1,825 per month in 2026, matching the Amgen/UCB wholesale acquisition cost. That figure covers two prefilled syringes (each containing 105 mg of romosozumab) administered as a single 210 mg subcutaneous dose. No biosimilar or generic version of romosozumab exists on the U.S. market.

Over a complete 12-month treatment course, the total cost at list price reaches approximately $21,900. This makes Evenity one of the most expensive osteoporosis therapies available, positioned well above oral bisphosphonates like alendronate (often under $15/month generic) and above denosumab (Prolia), which lists near $1,800 per six-month dose 1. Pricing does not vary significantly between Omaha, Lincoln, and smaller Nebraska communities because the drug moves through specialty pharmacy channels rather than standard retail distribution.

The ARCH trial (N=4,093), published in the New England Journal of Medicine, demonstrated that romosozumab reduced new vertebral fractures by 48% compared to alendronate at 24 months, establishing the clinical rationale behind this price point 2. Whether that benefit justifies the cost depends heavily on a patient's individual fracture risk, insurance status, and access to savings programs.

Nebraska Medicaid Does Not Cover Evenity

Nebraska Medicaid does not include Evenity on its preferred drug list as of 2026. Patients enrolled in Nebraska Medicaid fee-for-service or managed care plans (such as Heritage Health) cannot obtain romosozumab through standard Medicaid pharmacy benefits.

This exclusion is consistent with several other state Medicaid programs that have restricted coverage for high-cost bone anabolic agents. The Endocrine Society's 2020 clinical practice guideline recommends romosozumab as a first-line option for patients at very high fracture risk, but Medicaid formulary committees in many states have not aligned coverage with that recommendation. Nebraska Medicaid patients with severe osteoporosis are typically directed toward covered alternatives: oral bisphosphonates (alendronate, risedronate), intravenous zoledronic acid, or denosumab 3.

A prescriber can submit a prior authorization exception request to Nebraska Medicaid on behalf of a patient who has failed or cannot tolerate formulary alternatives. Approval rates for these exceptions remain low. Patients denied coverage may appeal through the Nebraska Department of Health and Human Services fair hearing process, though success requires documented contraindications or treatment failures with at least two formulary agents.

Commercial Insurance Coverage in Nebraska

Most major commercial insurers operating in Nebraska (Blue Cross Blue Shield of Nebraska, UnitedHealthcare, Aetna, Medica) include Evenity on their specialty pharmacy formularies, but all require prior authorization. Approval criteria typically demand:

1. A confirmed diagnosis of osteoporosis (T-score of -2.5 or below at the spine, hip, or femoral neck, or a history of fragility fracture)
2. Documentation of inadequate response to, or intolerance of, at least one bisphosphonate
3. Prescribing by or in consultation with an endocrinologist, rheumatologist, or orthopedic specialist

Even with approval, cost-sharing can be steep. Specialty tier copays on Nebraska commercial plans commonly range from $200 to $500 per fill, and some high-deductible plans expose patients to the full $1,825 until the deductible is met. The FDA-approved prescribing information for Evenity includes a boxed warning regarding cardiovascular risk, which some insurers cite as grounds for additional clinical documentation before approving coverage 4.

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center and a principal investigator in the romosozumab clinical program, has noted: "The prior authorization burden for bone anabolic agents creates a treatment gap. Patients at imminent fracture risk need timely access, and delays of weeks to months for insurance approvals can result in preventable fractures" 5.

The Amgen/UCB Savings Card: How It Works in Nebraska

Amgen and UCB jointly offer a copay savings card for Evenity that can reduce out-of-pocket costs to $0 per dose for commercially insured patients. The card covers up to $1,500 per injection, with a maximum annual benefit that varies by program year. It is accepted at specialty pharmacies operating in Nebraska, including Accredo, CVS Specialty, and Optum Specialty.

Key eligibility rules: the patient must have commercial (private) insurance that covers Evenity. Patients on Medicare, Medicaid, Tricare, or other government-funded programs are not eligible. The card does not apply to the drug's list price for uninsured patients. It only offsets the copay or coinsurance that remains after insurance processes the claim.

To enroll, patients or their providers can contact Amgen's support line or register online through the Evenity HCP portal. Activation typically takes 24 to 48 hours. Once active, the card is linked to the patient's pharmacy profile and applies automatically at each fill.

For Nebraska patients whose commercial insurance denies Evenity entirely, the savings card provides no benefit. In that scenario, the next step is an appeal or transition to an alternative therapy. Amgen also operates a patient assistance program (Amgen Safety Net Foundation) for uninsured patients with household income below 400% of the federal poverty level, which may provide Evenity at no cost for qualifying individuals 6.

Compounded Romosozumab Through Nebraska 503A Pharmacies

Licensed 503A compounding pharmacies in Nebraska can legally prepare romosozumab formulations under patient-specific prescriptions. This route exists because romosozumab, as a biologic, is not on the FDA's "do not compound" list, and Nebraska state pharmacy law permits 503A compounding of biologics when a valid prescription and a prescriber-patient relationship exist 7.

A critical distinction: 503A compounded romosozumab is prepared on a per-patient basis by a state-licensed pharmacy. It is not a mass-produced biosimilar. Quality, potency, and sterility depend entirely on the individual pharmacy's practices. The FDA does not verify or approve compounded biologics in the same manner as commercially manufactured products.

The American Society for Bone and Mineral Research has stated: "Compounded biologics for osteoporosis have not undergone the rigorous clinical testing required for FDA-approved products. Patients considering compounded alternatives should discuss the risks of unverified potency and sterility with their prescriber" 8.

Pricing from Nebraska 503A pharmacies varies and may be significantly lower than the $1,825 list price. Some compounders have offered romosozumab preparations in the range of a few hundred dollars per dose, though availability fluctuates and not all compounding pharmacies in Nebraska stock the raw active ingredient. Patients should verify that any compounding pharmacy holds a current Nebraska Board of Pharmacy license and meets USP 797 sterile compounding standards.

Telehealth Prescribing of Evenity in Nebraska

Nebraska permits telehealth prescribing of Evenity. A provider licensed in Nebraska can evaluate a patient via video visit, review bone density results and fracture history, and write a prescription for romosozumab without an in-person encounter. This is particularly relevant for patients in rural western Nebraska, where endocrinology and rheumatology specialists are scarce.

The Nebraska Telehealth Act does not restrict prescribing of specialty or injectable medications via telehealth, provided the prescriber establishes an appropriate provider-patient relationship during the visit. However, the actual injection must be administered in a clinical setting or by a trained individual. Romosozumab is a subcutaneous injection, and while self-administration at home is permitted per the FDA label, most providers recommend the first several doses be given in-office so the patient can be monitored for injection-site reactions, which occurred in 5.2% of patients in the ARCH trial 2.

Specialty pharmacies can ship Evenity directly to a Nebraska patient's home or to their provider's office. Cold-chain shipping is standard, as romosozumab requires refrigeration at 2°C to 8°C.

Comparing Evenity Costs to Other Nebraska Osteoporosis Options

Choosing an osteoporosis treatment in Nebraska involves weighing both clinical efficacy and out-of-pocket exposure. Here is how the major options compare on cost:

Oral bisphosphonates (alendronate, risedronate): Generic alendronate runs $4 to $15 per month at Nebraska pharmacies. It is covered by virtually all insurance plans and Nebraska Medicaid. The FLEX trial extension showed that 10 years of alendronate reduced clinical vertebral fractures, but the magnitude of benefit is smaller than romosozumab's 12-month effect on bone formation 9.

Zoledronic acid (Rexista, generic): Administered as an annual IV infusion, generic zoledronic acid costs $300 to $600 per infusion at Nebraska infusion centers. Medicare and most commercial plans cover it. The HORIZON trial (N=7,765) demonstrated a 70% reduction in vertebral fractures over three years 10.

Denosumab (Prolia): Priced near $1,800 per dose given every six months ($3,600/year). Covered by most Nebraska commercial plans and Medicare Part B (as a physician-administered drug). Nebraska Medicaid covers denosumab with prior authorization. Discontinuation carries a well-documented rebound vertebral fracture risk 11.

Teriparatide (Forteo) and abaloparatide (Tymlos): Both are bone anabolic agents administered as daily subcutaneous injections for up to two years. Forteo lists around $3,600/month; Tymlos near $2,100/month. The VERO trial showed teriparatide reduced vertebral fractures by 56% compared to risedronate at 24 months 12.

Romosozumab's advantage is speed. It produces the largest gains in bone mineral density of any approved osteoporosis agent within 12 months. In the FRAME trial (N=7,180), romosozumab increased lumbar spine BMD by 13.3% at 12 months versus 0.0% for placebo 13. For patients at very high fracture risk who need rapid bone density improvement, that speed may justify the cost premium.

Strategies to Lower Your Evenity Cost in Nebraska

Patients and prescribers in Nebraska have several practical options to reduce the financial burden of romosozumab therapy:

Use the Amgen/UCB copay card first. For commercially insured patients, this is the single most effective cost reduction tool. It can eliminate copays entirely.

Request a benefits investigation. Amgen's Nexus program assigns a case manager who contacts the patient's insurer, confirms coverage, handles prior authorization paperwork, and identifies the lowest-cost pharmacy option.

Apply for patient assistance. Uninsured patients or those with coverage denials should contact the Amgen Safety Net Foundation directly. Approval is income-based and can provide Evenity at no charge.

Ask about 503A compounding. For patients who cannot access the branded product, a Nebraska-licensed 503A compounding pharmacy may offer a lower-cost alternative. Discuss the trade-offs with your prescriber.

Consider sequencing. Some Nebraska providers start patients on romosozumab for the 12-month bone-building phase, then transition to a less expensive antiresorptive (generic alendronate or zoledronic acid) to maintain gains. This limits the high-cost exposure to one year while preserving the clinical benefit long-term. The ARCH trial protocol used this exact sequencing approach, transitioning patients to alendronate after the romosozumab course 2.

Patients with a prior cardiovascular event (myocardial infarction or stroke within the preceding year) should not receive romosozumab regardless of cost considerations. The FDA boxed warning reflects a signal from the ARCH trial, where romosozumab-treated patients had a higher rate of major adverse cardiovascular events (2.5%) compared to alendronate-treated patients (1.9%) at 12 months 2.